Opening the Doors to Advocacy

Mark Rosenberg's words aptly describe the mentality of the 435 Project™, an effort introduced to many readers of The Scientist 19 months ago.1 My opening paragraph in that summer article read, "There is a challenge that faces the entire scientific community .... [t]he opportunity to strengthen the call for doubling the United States' commitment to medical research looms larger than ever. It is time for the scientific community to elevate its advocacy, with a unified voice, to a volume not

Written byRay Merenstein
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Mark Rosenberg's words aptly describe the mentality of the 435 Project™, an effort introduced to many readers of The Scientist 19 months ago.1 My opening paragraph in that summer article read, "There is a challenge that faces the entire scientific community .... [t]he opportunity to strengthen the call for doubling the United States' commitment to medical research looms larger than ever. It is time for the scientific community to elevate its advocacy, with a unified voice, to a volume not yet heard by local, state, and national media and elected officials."

A year and a half later, those familiar with Research!America's signature grassroots program would surely agree that the 435 Project does not warehouse solutions. During the project's first two phases, Research!America and its partners have created, implemented, and evaluated a wide variety of messages, materials, and strategies. Throughout this time, best practices were identified and emulated by many local ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies